Brief: Liminal Biosciences Reports Q4 And Year Ended 2022 Financial Results
15/03/2023 20:09
March 15 (Reuters) - Liminal BioSciences Inc LMNL.O :
* LIMINAL BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR ENDED
2022
FINANCIAL RESULTS
* LIMINAL BIOSCIENCES INC - REGAINED COMPLIANCE WITH MINIMUM
BID
PRICE REQUIREMENT FOR CONTINUED LISTING ON NASDAQ CAPITAL MARKET
* LIMINAL BIOSCIENCES INC - CTA-ENABLING WORK ON TRACK TO
SEEK
APPROVAL TO COMMENCE PHASE 1 CLINICAL TRIAL OF LMNL6511 DURING
SECOND HALF OF 2023
Source text for Eikon: ID:nPnwd7lKa
Further company coverage: LMNL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Liminal BioSciences
See all newsBrief: Liminal Biosciences Announces Completion Of The Plan Of Arrangement With Structured Alpha Lp
Brief: Liminal Biosciences Files Amended Schedule 13E-3 And Supplement To Management Information Circular
Brief: Liminal Biosciences Obtains Interim Order For Proposed Arrangement With Structured Alpha Lp
U.S. STOCKS ON THE MOVE-Liminal Biosciences, Tesla, Quad/Graphics
U.S. STOCKS ON THE MOVE-T2 Biosystems, GoodRx Holdings, ShiftPixy